Journal of Istanbul Faculty of Medicine

SUBMITINFORMATION
EnglishTürkçe

Original Research


DOI :https://doi.org/10.18017/iuitfd.60951   IUP :https://doi.org/10.18017/iuitfd.60951    Full Text (PDF)

PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE

Berker Özkan, Erkan Kaba, Sedat Ziyade, Serhan Tanju, Murat Kapdağlı, Sedat Ziyade, Adalet Demir, Şükrü Dilege, Alper Toker

Objective: In this study, we aimed to analyse the non-small cell lung carcinoma patients who have undergone surgery after neoadjuvant chemo/chemoradiotherapy in regards to recurrences, survival, complication, morbidity, and mortality.

Materials and Methods: The data of 90 patients who had surgeries between June 2001 and December 2008 were retropectively evaluated. Fifty nine of those 90 patients had neoadjuvant chemotherapy and 31 patients had neoadjuvant chemoradiotherapy. Patients were divided into 3 groups; 47 patients were clinical T3/N2, 23 patients were clinical T4(N0-1), 20 patients were histopatologically proven N2(T1-3). Age, gender, tumor pathology, resection type, complications, mortality and survival rates of the patients were evaluated.

Results: There were 76 male, 14 female patients in our study group. Mean age was 55.3±8.5 (36-75) years. Thirty six patients had lobectomy, 11 patients had extended resections with lobectomy, 13 patients had sleeve lobectomy, and 30 patients had pneumonectomy operations. Major complication and mortality rates were 14.4% and 2.2% respectively. Minimal and mean follow-up periods were 24 and 27±18 months respectively. Mean survival was calculated as 25±4.6 months (pathological stage I: 35±9.7 months, stage II: 33±8.5 months, stage IIIa: 24±9.7 months, and stage IIIb: 14±10.9 months). Mean survival was 26±6.7 months in clinical T3/N2 group, 14±2.2 months in T4 group, 41±3.7 months in histopathological N2 group. There was a statisticaly significant difference in survival times between clinical T3/N2 and histopathological N2 groups (p<0.05).

Conclusion: Lung resections after neoadjuvant therapy can be achieved with acceptable rates of complications, morbidity, and mortality. Surgery in selected patients with proper mediastinal staging may also provide longer survival.


Keywords: Lung cancer, thoracic surgery, surgery after neoadjuvant treatment
DOI :https://doi.org/10.18017/iuitfd.60951   IUP :https://doi.org/10.18017/iuitfd.60951    Full Text (PDF)

PRİMER AKCİĞER KANSERİNDE NEOADJUVAN TEDAVİ UYGULANMIŞ HASTALARDA AKCİĞER REZEKSİYONLARI: İLK 90 OLGUNUN GÜNCEL BİLGİLERİMİZLE GÖZDEN GEÇİRİLMESİ

Berker Özkan, Erkan Kaba, Sedat Ziyade, Serhan Tanju, Murat Kapdağlı, Sedat Ziyade, Adalet Demir, Şükrü Dilege, Alper Toker

Amaç: Bu çalışmanın amacı neoadjuvan kemoterapi ve kemoradyoterapi sonrası cerrahi tedavi uygulanan primer akciğer tümörlü hastaların nüks, sağkalım, komplikasyon, morbidite ve mortalite açısından incelenmesidir.

Gereç ve Yöntem: Haziran 2001-Aralık 2008 tarihleri arasında 59’u neoadjuvan kemoterapi, 31’i ise neoadjuvan kemoradyoterapi sonrası opere edilen toplam 90 hasta retrospektif olarak 3 gruba ayrılarak incelendi: 47 klinik T3/N2, 23 T4 (N0-1), 20 histopatolojik olarak pozitif N2 (T1-3) hasta mevcuttu. Olguların yaşları, cinsiyetleri, tümör patolojileri, rezeksiyon tipleri, komplikasyonları, mortalite ve sağkalım oranları incelendi.

Bulgular: Hastaların 76’sı erkek, 14’ü kadındı. Yaş ortalaması 55.3±8.5 (36-75) idi. Olguların 36’sına lobektomi, 11’ine lobektomiyle birlikte genişletilmiş rezeksiyon, 13’üne sleeve lobektomi, 30’una pnömonektomi uygulandı. Tüm olguların major komplikasyon oranı %14.4, mortalite %2.2 idi. Minimal takip süresi 24 ay, ortalama takip süresi ise 27±18 aydı. Ortalama sağkalım oranı 25±4.6 ay; (patolojik evre I: 35±9.7 ay, evre II: 33±8.5 ay, evre IIIa: 24±9.7 ay ve evre IIIb: 14±10.9 ay) olarak hesaplandı. Ortalama sağkalım klinik T3/N2 grubunda 26±6.7 ay, T4 grubunda 14±2.2 ay ve histopatolojik N2 grubunda 41±3.7 aydı. Klinik T3/N2 grubu ile histopatolojik N2 grubunun sağkalım süreleri arasında istatistiksel olarak anlamlı fark saptandı (p<0.05).

Sonuç: Çalışmamızda neoadjuvan tedavi sonrası akciğer rezeksiyonlarının kabul edilebilir komplikasyon, morbiditemortalite oranlarıyla uygulanabileceği görülmüştür. Mediastinal lenf nodlarının tam ve doğru evrelendiği olgularda önemli oranda sağkalım avantajı sağladığı saptanmıştır. 

Keywords: Akciğer kanseri, göğüs cerrahisi, neoadjuvan tedavi sonrası cerrahi

PDF View

References

  • Jemal A, Siegel R, Ward E. Cancer Statistics. Cancer J Clin 2007;57:43-66. google scholar
  • İtil O. Akciğer kanserlerinin epidemiyolojisi ve etyolojisi. Haydaroğlu A (editör). Akciğer Kanserleri: Tanı ve Tedavi. Ege Üniversitesi Basımevi, İzmir, 2000;15-34. google scholar
  • Shield TW. General Features of Pulmonary Resections. In: Shields TW, LoCicero J, Ponn RB, Rusch VW (ed) General Thoracic Surgery. Lippincott Williams & Wilkins, Philadelphia, 6th ed., 2005;420-32 google scholar
  • Ginsberg RJ, Martini N. Non Small Lung Cancer, Surgical Management In Thoracic Surgery. In: Pearson FG, Cooper JD(ed). Thoracic Surgery. Churchill Livingstone, 2002;837-58. google scholar
  • Rusch V, Asamura H, Watanabe H, Giroux DJ, Porta RR, Goldstraw P. The IASLC Lung Cancer Project. A proposal for a new International Lymph Node Map in the forthcoming seventh edition of the TNM Classification for lung cancer. J Thorac Oncol. 2009; 4:568-77. google scholar
  • Ichinose Y, Fukuyama Y, Asoh H, Ushijima C, Okamoto T, Ikeda J, Okamoto J, Sakai M. Induction chemoradiotherapy and surgical resection for selected stage IIIB non–small-cell lung cancer. The Annals of Thoracic Surgery. 2003;76:1810-15. google scholar
  • Rendina EA, Venuta F, Giacomo TD, Ciccone AM, Ruvolo G, Coloni GF, Ricci C, Patterson GA. Induction chemotherapy for T4 centrally located non–small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:225-33 google scholar
  • Grunenwald DH, André F, Péchoux CL, Girard P,Lamer C, Laplanche A, Tarayre M, Arriagada R, Chevalier TL. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) NSCLC. J Thorac Cardiovasc Surg 2001;122:796- 802. google scholar
  • Doddoli C, Barlesi F, Trousse D, Robitail S, Yena S, Astoul P, Giudicelli R, Fuentes P, Thomas P. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 2005;130:416-25. google scholar
  • Alifano M, Boudaya MS, Salvi M, Collet JY, Dinu C, Broët SC, Régnard JF. Pneumonectomy After Chemotherapy: Morbidity, Mortality, and LongTerm Outcome. Ann Thorac Surg. 2008;85:1866-73. google scholar
  • Singhall S, Shrager JB, Larry R. Multimodality Therapy for Non Small Cell Lung Cancer. In: Shields TW, LoCicero J, Ponn RB, Rusch VW (ed). General Thoracic Surgery. Lippincott Williams & Wilkins Philadelphia, USA, 6th ed.,2005;p. 1653-79. google scholar
  • Martini N, Burt ME, Bains MS, McCormack PM, Rusch VW, Ginsberg RJ. Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg. 1992;54:460-5. google scholar
  • Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease innon-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes. J Thorac Cardiovasc Surg. 1994;107:1398-402. google scholar
  • Stamatis G, Eberhard W, Pöttgen C. Surgery after multimodality treatment for non-small-cell lung cancer. Lung Cancer 2004:2;107-12. google scholar
  • Burrows WM. Anatomical Lung Resection After Neoadjuvant Chemoradiotherapy. Semin Thorac Cardiovasc Surg 2007;19:360-5. google scholar
  • Weder W, Collaud S, Eberhardt WEE, Hillinger S, Welter S, Stahel R, Stamatis G. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010;139:1424-30. google scholar
  • Albain K, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fly WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JC. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-smallcell lung cancer: a phase III randomized controlled trial. Lancet. 2009;374:379-86. google scholar
  • Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd TA, Smith CJ, Gandara DR, Johnson DH, Green MR, Miller RC. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). Journal of Clinical Oncology. 2005;23:7014-27. google scholar
  • Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK. Concurrent cisplatin/Etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non–small cell lung cancer: mature results of Southwest Oncology Group phase II study 88-05. J Clin Oncol. 1995;13:1880-92. google scholar
  • Lilenbaum RC, Green MR. Multimodality therapy for non-small-cell lung cancer. Oncology (Huntingt) 1994; 8:25-31. google scholar
  • Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M. Concurrent cisplatin, etoposide and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys. 1996;35:343-50. google scholar
  • Elias AD, Skarin AT, Gonin R. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol 1994;17:26-33. google scholar
  • Keller SM. Prolonged survival in patients with resected NSCLC and single level N2 disease. J Thorac Surg 2004; 128: 130-37. google scholar
  • Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Prognosis of completely resected pN2 non-small cell lung carcinomas: What is the significant node that affects survival? J Thorac Cardiovasc Surg 1999;118:270-5. google scholar
  • Shields TW. The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non small cell carcinoma of the lung: a commentory. J Thorac Cardiovasc Surg 1990;99:48-53. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Özkan, B., Kaba, E., Ziyade, S., Tanju, S., Kapdağlı, M., Ziyade, S., Demir, A., Dilege, Ş., & Toker, A. (2016). PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE. Journal of Istanbul Faculty of Medicine, 79(1), 1-8. https://doi.org/https://doi.org/10.18017/iuitfd.60951


AMA

Özkan B, Kaba E, Ziyade S, Tanju S, Kapdağlı M, Ziyade S, Demir A, Dilege Ş, Toker A. PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE. Journal of Istanbul Faculty of Medicine. 2016;79(1):1-8. https://doi.org/https://doi.org/10.18017/iuitfd.60951


ABNT

Özkan, B.; Kaba, E.; Ziyade, S.; Tanju, S.; Kapdağlı, M.; Ziyade, S.; Demir, A.; Dilege, Ş.; Toker, A. PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 79, n. 1, p. 1-8, 2016.


Chicago: Author-Date Style

Özkan, Berker, and Erkan Kaba and Sedat Ziyade and Serhan Tanju and Murat Kapdağlı and Sedat Ziyade and Adalet Demir and Şükrü Dilege and Alper Toker. 2016. “PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE.” Journal of Istanbul Faculty of Medicine 79, no. 1: 1-8. https://doi.org/https://doi.org/10.18017/iuitfd.60951


Chicago: Humanities Style

Özkan, Berker, and Erkan Kaba and Sedat Ziyade and Serhan Tanju and Murat Kapdağlı and Sedat Ziyade and Adalet Demir and Şükrü Dilege and Alper Toker. “PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE.” Journal of Istanbul Faculty of Medicine 79, no. 1 (May. 2025): 1-8. https://doi.org/https://doi.org/10.18017/iuitfd.60951


Harvard: Australian Style

Özkan, B & Kaba, E & Ziyade, S & Tanju, S & Kapdağlı, M & Ziyade, S & Demir, A & Dilege, Ş & Toker, A 2016, 'PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE', Journal of Istanbul Faculty of Medicine, vol. 79, no. 1, pp. 1-8, viewed 22 May. 2025, https://doi.org/https://doi.org/10.18017/iuitfd.60951


Harvard: Author-Date Style

Özkan, B. and Kaba, E. and Ziyade, S. and Tanju, S. and Kapdağlı, M. and Ziyade, S. and Demir, A. and Dilege, Ş. and Toker, A. (2016) ‘PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE’, Journal of Istanbul Faculty of Medicine, 79(1), pp. 1-8. https://doi.org/https://doi.org/10.18017/iuitfd.60951 (22 May. 2025).


MLA

Özkan, Berker, and Erkan Kaba and Sedat Ziyade and Serhan Tanju and Murat Kapdağlı and Sedat Ziyade and Adalet Demir and Şükrü Dilege and Alper Toker. “PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE.” Journal of Istanbul Faculty of Medicine, vol. 79, no. 1, 2016, pp. 1-8. [Database Container], https://doi.org/https://doi.org/10.18017/iuitfd.60951


Vancouver

Özkan B, Kaba E, Ziyade S, Tanju S, Kapdağlı M, Ziyade S, Demir A, Dilege Ş, Toker A. PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE. Journal of Istanbul Faculty of Medicine [Internet]. 22 May. 2025 [cited 22 May. 2025];79(1):1-8. Available from: https://doi.org/https://doi.org/10.18017/iuitfd.60951 doi: https://doi.org/10.18017/iuitfd.60951


ISNAD

Özkan, Berker - Kaba, Erkan - Ziyade, Sedat - Tanju, Serhan - Kapdağlı, Murat - Ziyade, Sedat - Demir, Adalet - Dilege, Şükrü - Toker, Alper. “PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE”. Journal of Istanbul Faculty of Medicine 79/1 (May. 2025): 1-8. https://doi.org/https://doi.org/10.18017/iuitfd.60951



TIMELINE



SHARE



Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.